Clinical Takeaway
In a randomized, double-blind, placebo-controlled crossover trial of 29 autistic children aged 5 to 12, oral CBD oil dosed at 10 mg/kg/day was evaluated over 12-week treatment periods for effects on social relating, anxiety, and parental stress. The trial used a weight-based dosing protocol and included terpenes in the formulation, providing a more rigorous study design than much of the prior observational literature in this area. Results from this controlled study offer clinical evidence regarding whether CBD represents a viable pharmacological option for core and associated symptoms in pediatric autism spectrum disorder.
#28 Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.
Citation: Parrella Nina-Francesca et al.. Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.. Autism research : official journal of the International Society for Autism Research. 2026. PMID: 41452412.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 3 Human: 1 Risk: -2
- Preclinical only
Abstract: Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autism. We conducted a randomized, double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil containing terpenes can improve outcomes in autistic children. Twenty-nine children (18 male), aged 5 to 12 years (M = 9.62 years, SD = 2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10 mg/kg/day) or matched placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behavior Checklist-2 (DBC-2), Vineland-3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12 weeks (β = -11.15, SE = 7.19, p = 0.125). Significant improvements were observed in secondary measures of social functioning, including DBC-2 Social Relating (β = -2.35, SE = 0.92, p(adj) = 0.024), as well as reduced anxiety on the DBC-2 subscale (β = -3.20, SE = 0.94, p(adj) = 0.002), and lower parental stress (APSI; β = -4.63, SE = 2.26, p(adj) = 0.044). No differences were detected on Vineland-3 adaptive functioning (ABC: β = 2.06, SE = 2.67, p(adj) = 1.000), and domain scores were not significant. Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. Findings from this pilot trial suggest that while CBD combined with terpenes did not improve the primary outcome of social responsiveness, it may hold potential in addressing certain autism-related difficulties, particularly anxiety and social relating. Further research with larger sample sizes is needed to fully evaluate the efficacy
What This Study Teaches Us
CBD oil with terpenes did not improve the primary measure of social responsiveness (SRS-2) in autistic children over 12 weeks, but showed modest improvements in secondary measures of social relating, anxiety, and parental stress. The gap between null primary outcomes and positive secondary outcomes raises questions about what CBD actually targets in autism.
Why This Matters Clinically
Families and clinicians exploring CBD for autism need to know the evidence does not yet support claims that it meaningfully improves core social difficulties. However, if parents are already considering CBD, secondary benefits in anxiety and stress reduction might be relevant to individual decision-making, though the effect sizes are small.
Study Snapshot
| Study Design | Randomized double-blind placebo-controlled crossover trial |
| Population | 29 autistic children (18 male), ages 5 to 12 years (mean 9.62 years) |
| Intervention | Weight-based CBD oil at 10 mg/kg/day or matched placebo, two 12-week periods separated by 8-week washout |
| Primary Outcome | Social Responsiveness Scale-2 (SRS-2) |
| Key Result | CBD did not significantly improve SRS-2 versus placebo (p = 0.125); secondary improvements in DBC-2 social relating (p = 0.024), anxiety (p = 0.002), and parental stress (p = 0.044) |
Where This Paper Deserves Skepticism
This is a small pilot (N=29) that failed its primary endpoint, which alone limits confidence. The dissociation between null primary and positive secondary outcomes invites publication bias concerns and multiple comparisons inflation, particularly since secondary measures were measured but not pre-specified as coprimary. The abstract does not detail dropout rates, compliance verification, or whether the 8-week washout was adequate for a crossover design. Generalizability to children outside this narrow age and demographic window is unknown, and we do not know funding source or potential conflicts.
Dr. Caplan’s Take
I interpret this as a well-designed but underpowered pilot that found no benefit on the outcome measure that matters most clinically, the core social difficulties in autism. The secondary improvements in anxiety and parental stress are intriguing but modest in magnitude, and they may reflect placebo response, natural variation, or measurement error rather than a true drug effect when you consider the number of comparisons and the failure of the prespecified primary outcome. Until larger, pre-registered trials specifically powered for secondary outcomes emerge, I do not see enough here to recommend CBD as a treatment for autism’s social core, though individual families already committed to a trial might reasonably track their child’s anxiety or behavior empirically.
Clinical Bottom Line
CBD oil did not improve social responsiveness in this small trial, and while secondary measures showed modest gains, the failure of the primary outcome and small sample size do not yet support clinical use for autism. Families and clinicians should be cautious about claims that CBD improves core autism features.
|
Have thoughts on this? Share it:
